<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T20:03:48Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:5299464" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:5299464</identifier><datestamp>2017-02-22</datestamp><setSpec>blackwellopen</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Hum Mutat</journal-id>
      <journal-id journal-id-type="iso-abbrev">Hum. Mutat</journal-id>
      <journal-id journal-id-type="doi">10.1002/(ISSN)1098-1004</journal-id>
      <journal-id journal-id-type="publisher-id">HUMU</journal-id>
      <journal-title-group>
        <journal-title>Human Mutation</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1059-7794</issn>
      <issn pub-type="epub">1098-1004</issn>
      <publisher>
        <publisher-name>John Wiley and Sons Inc.</publisher-name>
        <publisher-loc>Hoboken</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC5299464</article-id>
      <article-id pub-id-type="pmcid">PMC5299464</article-id>
      <article-id pub-id-type="pmc-uid">5299464</article-id>
      <article-id pub-id-type="pmid">27676246</article-id>
      <article-id pub-id-type="doi">10.1002/humu.23123</article-id>
      <article-id pub-id-type="publisher-id">HUMU23123</article-id>
      <article-categories>
        <subj-group subj-group-type="overline">
          <subject>Research Article</subject>
        </subj-group>
        <subj-group subj-group-type="heading">
          <subject>Research Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>A Comprehensive Functional Analysis of <italic>NTRK1</italic> Missense Mutations Causing Hereditary Sensory and Autonomic Neuropathy Type IV (HSAN IV)</article-title>
        <alt-title alt-title-type="right-running-head">HUMAN MUTATION</alt-title>
      </title-group>
      <contrib-group>
        <contrib id="humu23123-cr-0001" contrib-type="author">
          <name>
            <surname>Shaikh</surname>
            <given-names>Samiha S.</given-names>
          </name>
          <xref ref-type="aff" rid="humu23123-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="humu23123-cr-0002" contrib-type="author">
          <name>
            <surname>Chen</surname>
            <given-names>YaâChun</given-names>
          </name>
          <xref ref-type="aff" rid="humu23123-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="humu23123-cr-0003" contrib-type="author">
          <name>
            <surname>Halsall</surname>
            <given-names>SallyâAnne</given-names>
          </name>
          <xref ref-type="aff" rid="humu23123-aff-0002">
<sup>2</sup>
</xref>
        </contrib>
        <contrib id="humu23123-cr-0004" contrib-type="author">
          <name>
            <surname>Nahorski</surname>
            <given-names>Michael S.</given-names>
          </name>
          <xref ref-type="aff" rid="humu23123-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="humu23123-cr-0005" contrib-type="author">
          <name>
            <surname>Omoto</surname>
            <given-names>Kiyoyuki</given-names>
          </name>
          <xref ref-type="aff" rid="humu23123-aff-0003">
<sup>3</sup>
</xref>
        </contrib>
        <contrib id="humu23123-cr-0006" contrib-type="author">
          <name>
            <surname>Young</surname>
            <given-names>Gareth T.</given-names>
          </name>
          <xref ref-type="aff" rid="humu23123-aff-0003">
<sup>3</sup>
</xref>
        </contrib>
        <contrib id="humu23123-cr-0007" contrib-type="author" corresp="yes">
          <name>
            <surname>Phelan</surname>
            <given-names>Anne</given-names>
          </name>
          <address>
            <email>Anne.Phelan@stratifiedmedical.com</email>
          </address>
          <xref ref-type="aff" rid="humu23123-aff-0004">
<sup>4</sup>
</xref>
        </contrib>
        <contrib id="humu23123-cr-0008" contrib-type="author" corresp="yes">
          <name>
            <surname>Woods</surname>
            <given-names>Christopher Geoffrey</given-names>
          </name>
          <address>
            <email>cw347@cam.ac.uk</email>
          </address>
          <xref ref-type="aff" rid="humu23123-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
      </contrib-group>
      <aff id="humu23123-aff-0001">
        <label>
          <sup>1</sup>
        </label>
        <named-content content-type="organisation-division">Cambridge Institute for Medical Research</named-content>
        <institution>University of Cambridge</institution>
        <named-content content-type="city">Cambridge</named-content>
        <named-content content-type="post-code">CB2 0XY</named-content>
        <country country="GB">UK</country>
      </aff>
      <aff id="humu23123-aff-0002">
        <label>
          <sup>2</sup>
        </label>
        <named-content content-type="organisation-division">Molecular Genetics Laboratory</named-content>
        <institution>Addenbrooke's Hospital</institution>
        <named-content content-type="city">Cambridge</named-content>
        <country country="GB">UK</country>
      </aff>
      <aff id="humu23123-aff-0003">
        <label>
          <sup>3</sup>
        </label>
        <named-content content-type="organisation-division">Neuroscience and Pain Research Unit</named-content>
        <institution>Pfizer Ltd</institution>
        <named-content content-type="city">Great Abington</named-content>
        <country country="GB">UK</country>
      </aff>
      <aff id="humu23123-aff-0004">
        <label>
          <sup>4</sup>
        </label>
        <institution>Stratified Medical</institution>
        <named-content content-type="city">London</named-content>
        <named-content content-type="country-part">NW1 1LW</named-content>
        <country country="GB">UK</country>
      </aff>
      <author-notes>
        <corresp id="correspondenceTo"><label>*</label>Correspondence to: Anne Phelan, Stratified Medical, 40 Churchway, London, NW1 1LW, UK. Eâmail: <email>Anne.Phelan@stratifiedmedical.com</email>; Christopher Geoffrey Woods, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, CB2 0XY, UK. Eâmail: <email>cw347@cam.ac.uk</email></corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>26</day>
        <month>11</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>1</month>
        <year>2017</year>
      </pub-date>
      <volume>38</volume>
      <issue>1</issue>
      <issue-id pub-id-type="doi">10.1002/humu.2017.38.issue-1</issue-id>
      <fpage>55</fpage>
      <lpage>63</lpage>
      <history>
        <date date-type="received">
          <day>29</day>
          <month>4</month>
          <year>2016</year>
        </date>
        <date date-type="rev-recd">
          <day>19</day>
          <month>8</month>
          <year>2016</year>
        </date>
        <date date-type="accepted">
          <day>07</day>
          <month>9</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2016 Wiley Periodicals, Inc. <copyright-statement>-->
        <copyright-statement content-type="article-copyright">Â© 2016 The Authors. <sup>**</sup><italic>Human Mutation</italic> published by Wiley Periodicals, Inc.</copyright-statement>
        <license license-type="creativeCommonsBy">
          <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <self-uri content-type="pdf" xlink:type="simple" xlink:href="file:HUMU-38-55.pdf"/>
      <abstract>
        <title>ABSTRACT</title>
        <p>Hereditary sensory and autonomic neuropathy type IV (HSAN IV) is an autosomal recessive disorder characterized by a complete lack of pain perception and anhidrosis. Here, we studied a cohort of seven patients with HSAN IV and describe a comprehensive functional analysis of seven novel <italic>NTRK1</italic> missense mutations, c.1550G &gt;A, c.1565G &gt;A, c.1970T &gt;C, c.2096T &gt;C, c.2254T &gt;A, c.2288G &gt;C, and c.2311C &gt;T, corresponding to p.G517E, p.G522E, p.L657P, p.I699T, p.C752S, p.C763S, and p.R771C, all of which were predicted pathogenic by in silico analysis. The results allowed us to assess the pathogenicity of each mutation and to gain novel insights into tropomyosin receptor kinase A (TRKA) downstream signaling. Each mutation was systematically analyzed for TRKA glycosylation states, intracellular and cell membrane expression patterns, nerve growth factor stimulated TRKA autophosphorylation, TRKAâY496 phosphorylation, PLCÎ³ activity, and neurite outgrowth. We showed a diverse range of functional effects: one mutation appeared fully functional, another had partial activity in all assays, one mutation affected only the PLCÎ³ pathway and four mutations were proved null in all assays. Thus, we conclude that complete abolition of TRKA kinase activity is not the only pathogenic mechanism underlying HSAN IV. By corollary, the assessment of the clinical pathogenicity of HSAN IV mutations is more complex than initially predicted and requires a multifaceted approach.</p>
      </abstract>
      <kwd-group kwd-group-type="author-generated">
        <kwd id="humu23123-kwd-0001">CIPA</kwd>
        <kwd id="humu23123-kwd-0002">TRKA</kwd>
        <kwd id="humu23123-kwd-0003">NGF</kwd>
        <kwd id="humu23123-kwd-0004">pain</kwd>
        <kwd id="humu23123-kwd-0005">neuropathy</kwd>
      </kwd-group>
      <funding-group>
        <award-group>
          <funding-source>Medical Research Council</funding-source>
          <award-id>MR/K017551/1</award-id>
        </award-group>
      </funding-group>
      <funding-group>
        <award-group>
          <funding-source>Cambridge Biomedical Research Campus</funding-source>
        </award-group>
      </funding-group>
      <counts>
        <fig-count count="6"/>
        <table-count count="1"/>
        <page-count count="9"/>
        <word-count count="6912"/>
      </counts>
      <custom-meta-group>
        <custom-meta>
          <meta-name>source-schema-version-number</meta-name>
          <meta-value>2.0</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>component-id</meta-name>
          <meta-value>humu23123</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>cover-date</meta-name>
          <meta-value>January 2017</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>details-of-publishers-convertor</meta-name>
          <meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.0.5 mode:remove_FC converted:09.02.2017</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
    <notes>
      <fn-group>
        <fn id="humu23123-note-0001">
          <p>Contract grant sponsors: Medical Research Council (MR/K017551/1); Cambridge Biomedical Research Campus</p>
        </fn>
        <fn id="humu23123-note-0002">
          <p>Communicated by MarÃ­aâJesÃºs Sobrido</p>
        </fn>
        <fn id="humu23123-note-0003">
          <p>The copyright line for this article was changed on 30 January 2017 after original online publication</p>
        </fn>
      </fn-group>
    </notes>
  </front>
  <body>
    <sec id="humu23123-sec-0010">
      <title>Introduction</title>
      <p>Pain is a physiological protective mechanism that is essential for the detection and prevention of contact with noxious stimuli present in all multicellular organisms [Dubin and Patapoutian, <xref rid="humu23123-bib-0013" ref-type="ref">2010</xref>]. Such noxious stimuli are detected by specialized sensory neurons called nociceptors. During development, specification toward a nociceptive phenotype relies on the expression of the receptor called tropomyosin receptor kinase A (TRKA) for the final transition from mitotic precursor to postâmitotic nociceptor [Marmigere and Ernfors, <xref rid="humu23123-bib-0025" ref-type="ref">2007</xref>]. Further underlining importance of TRKA in human pain is that either its deficiency or deficiency of its ligand, nerve growth factor (NGF), results in an inherited form of congenital painlessness named Hereditary Sensory and Autonomic Neuropathy type IV (HSAN IV) and HSAN V, respectively. In addition, novel antagonists or therapeutic antibodies against NGFâTRKA signaling are showing considerable promise as analgesics in clinical trials [Bannwarth and Kostine, <xref rid="humu23123-bib-0005" ref-type="ref">2014</xref>; Spierings <italic>etÂ al</italic>. <xref rid="humu23123-bib-0034" ref-type="ref">2014</xref>].</p>
      <p>The human TRKA protein is encoded by the gene <italic>NTRK1</italic> (MIM# 191315) located on chromosome 1q21âq22 (Fig. <xref rid="humu23123-fig-0001" ref-type="fig">1</xref>A). The first isoform of <italic>NTRK1</italic> includes all exons and yields a 796 residue protein that is predominantly expressed in neuronal tissues and provides responsiveness to both NGF and neurotrophin 3 [Barker <italic>etÂ al</italic>. <xref rid="humu23123-bib-0006" ref-type="ref">1993</xref>]. Exclusion of exon 9 in the second isoform results in a 790 residue protein that is primarily expressed in nonâneuronal tissues and binds NGF alone [Barker <italic>etÂ al</italic>. <xref rid="humu23123-bib-0006" ref-type="ref">1993</xref>]. Previous studies have shown TRKA to be synthesized as an 87Â kDa protein, which is immediately glycosylated to a 110Â kDa form. Further glycosylation events occur to produce the mature and functional 140Â kDa glycoprotein [MartinâZanca <italic>etÂ al</italic>. <xref rid="humu23123-bib-0026" ref-type="ref">1989</xref>], which is then trafficked to the plasma membrane [Watson <italic>etÂ al</italic>. <xref rid="humu23123-bib-0036" ref-type="ref">1999</xref>].</p>
      <fig fig-type="Figure" xml:lang="en" id="humu23123-fig-0001" orientation="portrait" position="float">
        <label>Figure 1</label>
        <caption>
          <p>TRKA structure, signaling, and identification of novel <italic>NTRK1</italic> mutations in patients with HSAN IV. <bold>A</bold>: <italic>NTRK1</italic> located on chromosome 1q21âq22, shown by the gray bar on the ideogram, consists of 17 exons and spans region of 25Â kb. Inclusion of all 17 exons encodes for the neuronal specific isoform of TRKA. <bold>B</bold>: The extracellular domain of TRKA consists of a number of structural domains: a leucine rich repeat, flanked on either side by a cysteine rich domain, and two immunoglobulinâlike domains. The majority of the intracellular domain comprises the kinase domain. <bold>C</bold>: Signaling through TRKA is initiated through NGF binding, TRKA dimerization, and autophosphorylation of Y676, Y680, and Y681. Subsequent phosphorylation of Y496 and Y791 leads to activation of downstream signaling cascades which drive neuronal differentiation and survival. <bold>D</bold>: Seven individuals were ascertained with a standard HSAN IV phenotype. The identified mutations were p.G517E, p.G522E, p.L657P, p.I699T, p.C752S, p.C763S, and p.R771C. Only the exons that code for the kinase domain are shown. TKD, tyrosine kinase domain.</p>
        </caption>
        <graphic id="nlm-graphic-3" xlink:href="HUMU-38-55-g001"/>
      </fig>
      <p>The TRKA receptor contains a single transmembrane domain that lies between the extracellular and intracellular domains. The extracellular domain consists of a number of structural motifs (Fig. <xref rid="humu23123-fig-0001" ref-type="fig">1</xref>B) which specifies binding to NGF, whereas the majority of the intracellular domain comprises a tyrosine kinase domain [Huang and Reichardt, <xref rid="humu23123-bib-0017" ref-type="ref">2003</xref>]. Intracellular signaling by TRKA is initiated by engagement with an extracellular NGF dimer, which causes the dimerization of two TRKA molecules (Fig. <xref rid="humu23123-fig-0001" ref-type="fig">1</xref>C) and autophosphorylation of the TRKA kinase domain tyrosine residuesY676, Y680, and Y681 [Cunningham <italic>etÂ al</italic>. <xref rid="humu23123-bib-0009" ref-type="ref">1997</xref>]. The subsequent structural change allows binding to ATP and results in phosphorylation of Y496 and Y791 [Cunningham and Greene, <xref rid="humu23123-bib-0010" ref-type="ref">1998</xref>; Artim <italic>etÂ al</italic>. <xref rid="humu23123-bib-0002" ref-type="ref">2012</xref>], which then act as adaptor sites for the downstream signaling molecules Shc and PLCÎ³, respectively, summarized in Figure <xref rid="humu23123-fig-0001" ref-type="fig">1</xref>C.</p>
      <p>Recruitment of Shc [Dikic <italic>etÂ al</italic>. <xref rid="humu23123-bib-0012" ref-type="ref">1995</xref>] and associated adaptor proteins to phosphorylated Y496 activates PI3K to promote neuronal survival [Datta <italic>etÂ al</italic>. <xref rid="humu23123-bib-0011" ref-type="ref">1999</xref>; Yuang and Yanker, <xref rid="humu23123-bib-0038" ref-type="ref">2000</xref>]. Binding of other associated adaptor proteins to Shc activates the Ras/MAPK pathway [Dikic <italic>etÂ al</italic>. <xref rid="humu23123-bib-0012" ref-type="ref">1995</xref>; MacDonald <italic>etÂ al</italic>. <xref rid="humu23123-bib-0023" ref-type="ref">2000</xref>] (Fig. <xref rid="humu23123-fig-0001" ref-type="fig">1</xref>C). PLCÎ³ bound to phosphorylated Y791 results in an increase in Ca<sup>2+</sup> levels and activation of Ca<sup>2+</sup>/calmodulinâregulated protein kinases [Obermeier <italic>etÂ al</italic>. <xref rid="humu23123-bib-0030" ref-type="ref">1993</xref>]. The Ras/MAPK and PLCÎ³ pathways converge to lead to transcription of genes that specifically drive neuronal differentiation [Riccio <italic>etÂ al</italic>. <xref rid="humu23123-bib-0031" ref-type="ref">1999</xref>; Lonze <italic>etÂ al</italic>. <xref rid="humu23123-bib-0021" ref-type="ref">2002</xref>].</p>
      <p>HSAN IV (OMIM #256800) is a rare autosomal recessive disorder that is caused by a failure of nociceptive and sympathetic neuron development. One of the characteristic features of HSAN IV is a congenital and complete insensitivity to both superficial and deep painful stimuli. Patients are prone to oral injuries as well as multiple accidental injuries such as burns, falls, and bone and joint fractures [Amano <italic>etÂ al</italic>. <xref rid="humu23123-bib-0001" ref-type="ref">1998</xref>; BarâOn <italic>etÂ al</italic>. <xref rid="humu23123-bib-0007" ref-type="ref">2002</xref>]. Further key features of HSAN IV are a deficit of temperature sensing [Ismail <italic>etÂ al</italic>. <xref rid="humu23123-bib-0018" ref-type="ref">1998</xref>; Axelrod <xref rid="humu23123-bib-0003" ref-type="ref">2002</xref>] and developmental delay which becomes apparent within the first decade [Rosemberg <italic>etÂ al</italic>. <xref rid="humu23123-bib-0032" ref-type="ref">1994</xref>]. Recently it has been shown that lack of TRKA signaling increases the susceptibility of patients to infections, in particular to <italic>Staphylococcus aureus</italic>, through a monocyte/macrophageâspecific NGF/TRKA pathway [Beiglman <italic>etÂ al</italic>. <xref rid="humu23123-bib-0008" ref-type="ref">2009</xref>; Hepburn <italic>etÂ al</italic>. <xref rid="humu23123-bib-0016" ref-type="ref">2014</xref>].</p>
      <p>Many different mutations have been identified in HSAN IV patients, mostly nonsense mutations, but also missense, small insertions, small deletions, and splicing variants. Only a small number of missense mutations have previously been functionally analyzed (review of information in Supp. Table S1), the mutations p.G516R, p.G571R, p.R643W, p.R648C, p.G708S, and p.R774P (numbering based on RefSeq ID NP_001012331). All showed diminished kinase activity and absent autophosphorylation [Greco <italic>et al</italic>. <xref rid="humu23123-bib-0014" ref-type="ref">1999</xref>; Greco <italic>etÂ al</italic>. <xref rid="humu23123-bib-0015" ref-type="ref">2000</xref>; Mardy <italic>etÂ al</italic>. <xref rid="humu23123-bib-0024" ref-type="ref">2001</xref>; Miranda <italic>etÂ al</italic>. <xref rid="humu23123-bib-0027" ref-type="ref">2002</xref>], and in addition, the extracellular domain mutations p.L93P and p.L213P were aberrantly processed and showed reduced kinase activity [Mardy <italic>etÂ al</italic>. <xref rid="humu23123-bib-0024" ref-type="ref">2001</xref>; Miranda <italic>etÂ al</italic>. <xref rid="humu23123-bib-0027" ref-type="ref">2002</xref>].</p>
      <p>We have identified seven novel missense mutations in <italic>NTRK1</italic> from patients with HSAN IV. Extensive functional analysis of each mutation revealed a diverse and novel range of results and suggests multiple pathogenic mechanisms underlie HSAN IV.</p>
    </sec>
    <sec id="humu23123-sec-0020">
      <title>Methods</title>
      <sec id="humu23123-sec-0030">
        <title>Molecular Genetics, Sequencing, and Segregation Studies</title>
        <p>The seven missense mutations described in this study were sequentially ascertained through an NHS genetics service. Patients were accepted for analysis if they had the minimal clinical characteristics of both a congenital pain insensitivity and cognitive delay. Sequencing was by standard Sanger analysis of each exon of <italic>NTRK1</italic> (RefSeq ID NM_002529.3) using a customized set of primers designed to work under identical PCR conditions (primer sequences are available on request). The <italic>NGF</italic> gene (RefSeq ID NM_002506.2) was also sequenced using a set of primers designed to work under identical conditions.</p>
        <p>The conservation of the mutated residues was analyzed using the multiple sequence alignment tool Clustl Omega version 1.2.2 (McWilliam <italic>etÂ al</italic>. 2013) (<ext-link ext-link-type="uri" xlink:href="http://www.ebi.ac.uk/Tools/msa/clustalo/">http://www.ebi.ac.uk/Tools/msa/clustalo/</ext-link>). Pathogenicity of mutations was predicted by PolyPhenâ2 [Adzhubei <italic>etÂ al</italic>. <xref rid="humu23123-bib-0004" ref-type="ref">2010</xref>] (<ext-link ext-link-type="uri" xlink:href="http://genetics.bwh.harvard.edu/pph2/">http://genetics.bwh.harvard.edu/pph2/</ext-link>) and by SIFT [Kumar <italic>etÂ al</italic>. <xref rid="humu23123-bib-0020" ref-type="ref">2009</xref>] (<ext-link ext-link-type="uri" xlink:href="http://sift.jcvi.org/www/SIFT_enst_submit.html">http://sift.jcvi.org/www/SIFT_enst_submit.html</ext-link>). For all tools, default settings were used. Our chromosome and mutation lab results have been uploaded on DECIPHER (<ext-link ext-link-type="uri" xlink:href="https://decipher.sanger.ac.uk">https://decipher.sanger.ac.uk</ext-link>), where they are freely available, under an agreement with NHSâCAM and also on LOVD database (<ext-link ext-link-type="uri" xlink:href="http://grenada.lumc.nl/LSDB_list/lsdbs/NTRK1">http://grenada.lumc.nl/LSDB_list/lsdbs/NTRK1</ext-link>).</p>
      </sec>
      <sec id="humu23123-sec-0040">
        <title>Cloning of Expression Constructs</title>
        <p>The construct for wildâtype fullâlength TRKA was obtained from IMAGE clones (Source BioSciences, Cambridge, UK). A Câterminal GFP tagged TRKA construct was generated by introducing fullâlength <italic>NTRK1</italic> cDNA into the pEGFPâN1 cloning vector (Clontech, Mountain View, CA, USA) as described previously [Mitchell <italic>etÂ al</italic>. <xref rid="humu23123-bib-0028" ref-type="ref">2012</xref>], and henceforth referred to as wildâtype TRKAâGFP. GFP tagged TRKA had a similar activity to untagged TRKA (Supp. Fig. S1). All the point mutations were introduced using the QuikChange II Siteâdirected Mutagenesis Kit (Agilent Technologies, Santa Clara, CA, USA).</p>
      </sec>
      <sec id="humu23123-sec-0050">
        <title>Cell Culture and Conditions</title>
        <p>HEKâ293, HeLa, and SHâSY5Y cells were cultured in complete DMEM supplemented with 10% FBS, 2Â mM <sc>l</sc>âglutamine and 100Â Î¼g/ml penicillin and 100Â Î¼g/ml streptomycin, at 37Â°C and 5% CO<sub>2</sub>.</p>
        <p>For localization studies, HEKâ293 cells were plated on polyâ<sc>l</sc>âlysine coated coverslips at a seeding concentration of 1Â ÃÂ 10<sup>5</sup>Â cells/ml. For neurite outgrowth, SHâSY5Y cells were plated on polyâ<sc>l</sc>âlysine coated coverslips at 5Â ÃÂ 10<sup>4</sup>Â cells/ml. Cells were transiently transfected with 500Â ng DNA with Fugene HD transfection reagent (Promega, Madison, WI, USA).</p>
        <p>For glycosylation assessment, HEKâ293 cells were plated at a seeding concentration 2.5Â ÃÂ 10<sup>5</sup>Â cells/ml. For phosphoâELISA assays and calcium imaging, HeLa cells were plated at 1.25Â ÃÂ 10<sup>5</sup>Â cells/ml. For calcium imaging, cells were plated on polyâ<sc>l</sc>âlysine coated 35Â mm glass bottom dishes. In all cases, cells were transiently transfected with 2.5Â Î¼g DNA using Fugene HD for 24Â hr.</p>
      </sec>
      <sec id="humu23123-sec-0060">
        <title>Colocalization Analysis</title>
        <p>Twentyâfour hours postâtransfection, HEKâ293 cells were washed in PBS and fixed in iceâcold methanol. Cells were stained with GFP antibody (Abcam, Cambridge, UK; ab6556, 1:1000) and Na<sup>+</sup>/K<sup>+</sup> ATPase Î±1 subunit antibody (Abcam; ab7671, 1:300). Alexaâ488 and Alexaâ546 conjugated secondary antibodies were purchased from Invitrogen, Carlsbad, CA, USA (1:1,000). All images were acquired with an LSM710 laserâscanning META confocal microscope (Carl Zeiss, Oberkochen, Germany) using a Ã63 oilâimmersion objective.</p>
        <p>Image analysis was performed using the Volocity image analysis software (PerkinElmer, Waltham, MA, USA). Colocalization was quantified in terms of Manders M1 coefficient. The proportion of GFP at the membrane was quantified by measuring the GFP at the plasma membrane and dividing by the total GFP fluorescence.</p>
      </sec>
      <sec id="humu23123-sec-0070">
        <title>Glycosylation Assessment</title>
        <p>Transfected HEKâ293 cells were washed with 1Ã PBS and scraped in RIPA buffer (Tris pH 7.4, NaCl 150Â mM, EDTA, 0.5Â mM, 1% Triton), containing protease inhibitors (Roche Applied Sciences, Penzberg, Germany). Lysates were cleared by centrifugation at 16,000<italic>g</italic> at 4Â°C for 25Â min and levels of total cellular protein tested using the DC protein assay kit (BioRad, Hercules, CA, USA). Total protein (25Â Î¼g) was treated with PNGase (NEB) following manufacturer's protocol or was left untreated.</p>
        <p>PNGaseâtreated and âuntreated protein lysate were separated using 6% Trisâglycine gels (Invitrogen) and transferred to PVDF membrane (Millipore, Billerica, MA, USA). Blots were then probed with GFP (D5.1) XP Rabbit mAb #2956 (Cell Signaling Technologies, Danvers, MA, USA; 1:1,000) and lamin antibody (Abcam; ab133741, 1:1000). Secondary antibodies were purchased from Dako (Santa Clara, CA, USA) and signal was detected using the chemiluminescent HRP substrate (Millipore). Densitometry was performed with ImageJ software (NIH).</p>
      </sec>
      <sec id="humu23123-sec-0080">
        <title>PhosphoâTRKA Assays</title>
        <p>Twentyâfour hours post transfection, HeLa cells were serum starved in DMEM supplemented with 1% FBS at 37Â°C for 1Â hr. Cells were then treated with 100Â ng/ml NGF (CST) for 5Â min at 37Â°C or were left untreated and washed in 1Ã Tris buffered saline. Lysate was collected as mentioned previously, with one alteration: RIPA buffer was supplemented with a 1:100 dilution of phosphatase inhibitor cocktails 2 and 3 (Sigma, St Louis, MO, USA).</p>
        <p>The autophosphorylation and Y496 phosphorylation levels were determined using the PathScanÂ® PhosphoâTRKA Sandwich ELISA 674/675 Kit (CST) and PathScanÂ® PhosphoâTRKA Tyr490 Sandwich ELISA kit (CST), respectively, following manufacturer's protocol. Total TRKA levels in the lysates were also measured using PathScanÂ® Total TRKA Sandwich ELISA kit (CST).</p>
        <p>The relative levels of phosphorylated TRKA were calculated by dividing phosphorylated values by total TRKA values. This was then normalized to the relative phosphorylation of wildâtype transfected cells without NGF treatment.</p>
      </sec>
      <sec id="humu23123-sec-0090">
        <title>Calcium Imaging</title>
        <p>Twentyâfour hours postâtransfection, calcium imaging was performed on HeLa cells using Rhodâ3âAM calcium imaging kit (Invitrogen) following manufacturer's protocol. Images were acquired with an LSM710 laser scanning META confocal microscope (Carl Zeiss) using a Ã20 objective and maximum pinhole aperture of 600Â Î¼m. Two line averages were performed for each frame with images taken every 4Â sec.</p>
        <p>At <italic>t</italic>Â =Â 48Â sec, 20Â Î¼l of HBSS media was added, at <italic>t</italic>Â =Â 140Â sec, 20Â Î¼l NGF (final concentration of 100Â ng/ml) was added to the cells. The response to NGF was monitored for 10Â min, after which at <italic>t</italic>Â =Â 820Â sec, 100Â ng/ml ionomycin was added. For PLCÎ³ inhibition studies, WT transfected cells were treated with 3Â Î¼g/ml of U73122 (Calbiochem, Billerica, MA, USA) for 30Â min prior to NGF stimulation.</p>
        <p>Image analysis was performed with the Volocity 3D Image Analysis Software using green cells that did not spontaneously fluoresce and had an ionomycin response.</p>
      </sec>
      <sec id="humu23123-sec-0100">
        <title>Neurite Outgrowth Assays</title>
        <p>Twentyâfour hours post transfection, SHâSY5Y cells were treated with 100Â ng/ml NGF in DMEM supplemented with 5% FBS for 9 days, with media being replaced every 3 days. Cells were then washed in PBS and fixed in 4% paraformaldehyde and were imaged with an LSM510 laser scanning META confocal microscope (Carl Zeiss) using a Ã40 immersion oil objective. Cells were analyzed using the ImageJ software. A neurite was identified as being more than twice the cell body length, where the longest dimension was used [Nahorski <italic>etÂ al</italic>. <xref rid="humu23123-bib-0029" ref-type="ref">2015</xref>]. Total neurite length per cell was also quantified where all extensions were measured and divided by the total number of cells counted [Nahorski <italic>etÂ al</italic>. <xref rid="humu23123-bib-0029" ref-type="ref">2015</xref>].</p>
      </sec>
      <sec id="humu23123-sec-0110">
        <title>Structural Modeling</title>
        <p>The homology model of the human TRKA tyrosine kinase domain (UniProtKB: P04629) was created using inâhouse Pfizer software and Modeler 9v8 (<ext-link ext-link-type="uri" xlink:href="http://salilab.org/modeller/">http://salilab.org/modeller/</ext-link>) [Sali and Blundell, <xref rid="humu23123-bib-0033" ref-type="ref">1993</xref>] using human TRKA structures 4AOJ_A, 4GT5, 4PM, 4PP, 4PS, and 4PT, deposited in the Protein Data Bank as templates, <ext-link ext-link-type="uri" xlink:href="http://www.rcsb.org/pdb/home/home.do">http://www.rcsb.org/pdb/home/home.do</ext-link>, as previously described [Veale <italic>etÂ al</italic>. <xref rid="humu23123-bib-0035" ref-type="ref">2014</xref>].</p>
      </sec>
      <sec id="humu23123-sec-0120">
        <title>Statistical Analysis</title>
        <p>The data show the meanÂ Â±Â standard error of the mean (SEM). Statistical significance was calculated using a oneâway ANOVA, followed by unpaired, two sided Student's <italic>t</italic>âtest using a Bonferroni corrected adjusted <italic>P</italic> value. Significance was set at <sup>*</sup>
<italic>P</italic>Â &lt;Â 0.05, <sup>**</sup>
<italic>P</italic>Â &lt;Â 0.01, or <sup>***</sup>
<italic>P</italic>Â &lt;Â 0.001.</p>
      </sec>
    </sec>
    <sec id="humu23123-sec-0130">
      <title>Results</title>
      <sec id="humu23123-sec-0140">
        <title>Putative Mutations in <italic>NTRK1</italic>
</title>
        <p>Seven cases with a typical HSAN IV phenotype, in which parents had no features of HSAN IV, were referred to the East Anglian NHS Genetics Services for HSAN IV analysis and were sequentially identified. The probands ages were from 3 to 15 years. They had no evidence of having pain or temperature perception, had cognitive global delay ranging from mild to moderate. They did not sweat and usually had ichthyotic areas of skin with troublesome pruritus. Those over 10 years of age had evidence of Charcot's joints in the lower limbs, and had had at least one significant episode of <italic>S. aureus</italic> infection. (For full clinical and mutation details, see Supp. Table S2.) Four cases were consanguineous, whilst three cases were from singleton families. Through sequencing analysis, we found three individuals who were homozygous for different <italic>NTRK1</italic> mutations, two cases with a heterozygous missense mutation and a heterozygous nonsense mutation and one case with two heterozygous missense mutations. Sequencing of both parents in all cases confirmed that the mutations segregated as expected for an autosomal recessive disorder. <italic>NGF</italic> was also sequenced and contained no mutations. The novel identified mutations were c.1550G&gt;A, c.1565G&gt;A, c.1970T&gt;C, c.2096T&gt;C, c.2254T&gt;A, c.2288G&gt;C, c.2311C&gt;T (RefSeq ID NM_002529.3), corresponding to the TRKA protein changes p.G517E, p.G522E, p.L657P, p.I699T, p.C752S, p.C763S, and p.R771C, respectively (Fig. <xref rid="humu23123-fig-0001" ref-type="fig">1</xref>D and Supp. Fig. S2). Nucleotide numbering uses +1 as the A of the ATG translation initiation codon in the reference sequence, with the initiation codon as codon 1. There are no variations at these positions recorded in the 1000 Genomes Server, dbSNP (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/">http://www.ncbi.nlm.nih.gov/SNP/</ext-link>), the Exome Variant Server (<ext-link ext-link-type="uri" xlink:href="http://evs.gs.washington.edu/EVS/">http://evs.gs.washington.edu/EVS/</ext-link>), or the ExAC database (<ext-link ext-link-type="uri" xlink:href="http://exac.broadinstitute.org">http://exac.broadinstitute.org</ext-link>). p.G522R (called p.G516R in the article) has previously been reported in a HSAN IV case [Mardy <italic>etÂ al</italic>. <xref rid="humu23123-bib-0024" ref-type="ref">2001</xref>]. Interestingly, all of the mutations identified here were located intracellularly within the kinase domain (Supp. Figs. S2 and S3), as is the case for most of the previously described missense mutations in <italic>NTRK1</italic>. All mutations were in evolutionarily conserved residues and were predicted to be pathogenic by Polyphen and SIFT (Supp. Fig. S3). As none of the mutations would be expected to cause a loss of or instability of the TRKA protein, a number of different studies were undertaken to determine the pathogenic mechanism. Table <xref rid="humu23123-tbl-0001" ref-type="table-wrap">1</xref> summarizes the results.</p>
        <table-wrap id="humu23123-tbl-0001" xml:lang="en" orientation="portrait" position="float">
          <label>Table 1</label>
          <caption>
            <p>Summary of Functional Characterization of New TRKA Mutations</p>
          </caption>
          <table frame="hsides" rules="groups">
            <col align="left" span="1"/>
            <col align="left" span="1"/>
            <col align="left" span="1"/>
            <col align="left" span="1"/>
            <col align="left" span="1"/>
            <col align="left" span="1"/>
            <col align="left" span="1"/>
            <col align="left" span="1"/>
            <thead>
              <tr>
                <th align="left" rowspan="1" colspan="1">
<bold><italic>NTRK1</italic> mutation</bold>
</th>
                <th align="center" rowspan="1" colspan="1">
<bold>TRKA protein</bold>
</th>
                <th align="center" rowspan="1" colspan="1">
<bold>Full glycosylation</bold>
</th>
                <th align="center" rowspan="1" colspan="1">
<bold>Membrane expression</bold>
</th>
                <th align="center" rowspan="1" colspan="1">
<bold>Autophosâphorylation</bold>
</th>
                <th align="center" rowspan="1" colspan="1">
<bold>Y496 phosâphorylation</bold>
</th>
                <th align="center" rowspan="1" colspan="1">
<bold>PLCÎ³ activation</bold>
</th>
                <th align="center" rowspan="1" colspan="1">
<bold>Neurite outgrowth</bold>
</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" rowspan="1" colspan="1">c.1550G &gt; A</td>
                <td align="left" rowspan="1" colspan="1">p.G517E</td>
                <td align="left" rowspan="1" colspan="1">No effect</td>
                <td align="left" rowspan="1" colspan="1">No effect</td>
                <td align="left" rowspan="1" colspan="1">No effect</td>
                <td align="left" rowspan="1" colspan="1">No effect</td>
                <td align="left" rowspan="1" colspan="1">Abolished</td>
                <td align="left" rowspan="1" colspan="1">Reduced</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">c.1565G &gt; A</td>
                <td align="left" rowspan="1" colspan="1">p.G522E</td>
                <td align="left" rowspan="1" colspan="1">No effect</td>
                <td align="left" rowspan="1" colspan="1">No effect</td>
                <td align="left" rowspan="1" colspan="1">Abolished</td>
                <td align="left" rowspan="1" colspan="1">Abolished</td>
                <td align="left" rowspan="1" colspan="1">Abolished</td>
                <td align="left" rowspan="1" colspan="1">
<sup>â</sup>
</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">c.1970T &gt; C</td>
                <td align="left" rowspan="1" colspan="1">p.L657P</td>
                <td align="left" rowspan="1" colspan="1">Reduced</td>
                <td align="left" rowspan="1" colspan="1">Reduced</td>
                <td align="left" rowspan="1" colspan="1">Abolished</td>
                <td align="left" rowspan="1" colspan="1">Abolished</td>
                <td align="left" rowspan="1" colspan="1">Abolished</td>
                <td align="left" rowspan="1" colspan="1">Abolished</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">c.2096T &gt; C</td>
                <td align="left" rowspan="1" colspan="1">p.I699T</td>
                <td align="left" rowspan="1" colspan="1">Reduced</td>
                <td align="left" rowspan="1" colspan="1">Reduced</td>
                <td align="left" rowspan="1" colspan="1">Abolished</td>
                <td align="left" rowspan="1" colspan="1">Abolished</td>
                <td align="left" rowspan="1" colspan="1">Abolished</td>
                <td align="left" rowspan="1" colspan="1">
<sup>â</sup>
</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">c.2254T &gt; A</td>
                <td align="left" rowspan="1" colspan="1">p.C752S</td>
                <td align="left" rowspan="1" colspan="1">No effect</td>
                <td align="left" rowspan="1" colspan="1">No effect</td>
                <td align="left" rowspan="1" colspan="1">No effect</td>
                <td align="left" rowspan="1" colspan="1">No effect</td>
                <td align="left" rowspan="1" colspan="1">No effect</td>
                <td align="left" rowspan="1" colspan="1">No effect</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">c.2288G &gt; C</td>
                <td align="left" rowspan="1" colspan="1">p.C763S</td>
                <td align="left" rowspan="1" colspan="1">Reduced</td>
                <td align="left" rowspan="1" colspan="1">Reduced</td>
                <td align="left" rowspan="1" colspan="1">Reduced</td>
                <td align="left" rowspan="1" colspan="1">Reduced</td>
                <td align="left" rowspan="1" colspan="1">Reduced</td>
                <td align="left" rowspan="1" colspan="1">Reduced</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">c.2311C&gt;T</td>
                <td align="left" rowspan="1" colspan="1">p.R771C</td>
                <td align="left" rowspan="1" colspan="1">Reduced</td>
                <td align="left" rowspan="1" colspan="1">Reduced</td>
                <td align="left" rowspan="1" colspan="1">Abolished</td>
                <td align="left" rowspan="1" colspan="1">Abolished</td>
                <td align="left" rowspan="1" colspan="1">Abolished</td>
                <td align="left" rowspan="1" colspan="1">
<sup>â</sup>
</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="humu23123-tbl1-note-0001">
              <p>GFP tagged constructs of wildâtype TRKA and each mutation were used to asses pathogenicity (RefSeq ID NM_002529.3, NP_002520).</p>
            </fn>
          </table-wrap-foot>
          <permissions>
            <copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder>
          </permissions>
        </table-wrap>
      </sec>
      <sec id="humu23123-sec-0150">
        <title>Glycosylation Changes in TRKA Mutants</title>
        <p>We first determined whether the mutations affected protein synthesis or postâtranslational modification. Câterminal tagged GFP wildâtype and mutant constructs were transfected into HEKâ293 cells and lysates were collected and were either treated with peptideâNâglycosidase (PNGase) or were left untreated. PNGase treatment of wildâtype and mutant lysate removed Nâglycosylation to yield an unglycosylated backbone of 117Â kDa (Fig. <xref rid="humu23123-fig-0002" ref-type="fig">2</xref>A). Untreated lysate of wildâtype TRKAâGFP had two protein bands: the fully glycosylated 170Â kDa product and the partially glycosylated 140Â kDa product. All of the mutants clearly showed the 170Â kDa fully glycosylated and 140Â kDa partially glycosylated products. However, compared with wildâtype TRKAâGFP, p.L657P showed a fourfold reduction in the fully glycosylated form, whilst p.I699T and p.R771C showed a 2.5âfold reduction (<sup>**</sup>
<italic>P</italic>Â &lt;Â 0.01; Fig. <xref rid="humu23123-fig-0002" ref-type="fig">2</xref>B). p.C763S also showed a 1.3âfold reduction in the 170Â kDa form (<sup>*</sup>
<italic>P</italic>Â &lt;Â 0.05; Fig. <xref rid="humu23123-fig-0002" ref-type="fig">2</xref>B). p.G517E, p.G522E, and p.C752S showed a glycosylation pattern that was similar to wildâtype TRKAâGFP.</p>
        <fig fig-type="Figure" xml:lang="en" id="humu23123-fig-0002" orientation="portrait" position="float">
          <label>Figure 2</label>
          <caption>
            <p>Expression, processing, and localization of wildâtype and mutant TRKA. <bold>A</bold>: Expression of Câterminal GFP tagged wildâtype and mutant TRKA constructs in transfected HEKâ293 cells. The lanes â+â and âââ represent lysates treated with/without PNGase respectively. Lamin B1 was included as a loading control. Representative image of <italic>n</italic>Â =Â 3 is shown. WT, wildâtype; EV, empty vector. <bold>B</bold>: Quantification of relative levels of fully glycosylated 170Â kDa TRKAâGFP protein to the levels of partially glycosylated 130Â kDa TRKAâGFP protein. <bold>C</bold>: Localization of TRKAâGFP wildâtype and mutant proteins in transfected HEKâ293 cells. The cells were stained against GFP (green) and the plasma membrane marker Na<sup>+</sup>/K<sup>+</sup> ATPase (red). Wildâtype TRKA and all the mutants show membrane expression. <bold>D</bold>: Relative levels of GFP at the membrane compared with the levels of GFP in the cytoplasm. Graph represents mean values of <italic>n</italic>Â =Â 3, with at least 15 cells in each repeat, and error bars represent standard error of the mean.</p>
            <p>Statistical differences are indicated as <sup>*</sup>
<italic>P</italic>Â &lt;Â 0.05, <sup>**</sup>
<italic>P</italic>Â &lt;Â 0.01 (oneâway ANOVA, followed by Student's <italic>t</italic>âtest using a Bonferroni adjusted <italic>P</italic> value).</p>
          </caption>
          <graphic id="nlm-graphic-5" xlink:href="HUMU-38-55-g002"/>
        </fig>
      </sec>
      <sec id="humu23123-sec-0160">
        <title>Localization of TRKAâGFP Mutant Proteins</title>
        <p>We then determined the localization of the mutant TRKAâGFP proteins to see whether the glycosylation changes observed affected the subcellular localization. HEKâ293 cells were transfected with wildâtype and mutant constructs and were stained with antibodies against GFP, shown in green, and the plasma membrane marker Na<sup>+</sup>/K<sup>+</sup> ATPase Î±1 subunit, shown in red (Fig. <xref rid="humu23123-fig-0002" ref-type="fig">2</xref>C). As previously observed, wildâtype TRKAâGFP was present around the periphery of the cells and colocalized with Na<sup>+</sup>/K<sup>+</sup> ATPase staining (Supp. Fig. S4). Staining of wildâtype TRKAâGFP demonstrated that 45% of the protein was located at the cell surface with the remainder being located intracellularly (Fig. <xref rid="humu23123-fig-0002" ref-type="fig">2</xref>D). This was not significantly different in cells expressing the p.G517E, p.G522E, or p.C752S mutations. Although the remaining mutant proteins colocalized at the plasma membrane, the proportion of GFP at the membrane was significantly reduced to approximately 20% to that of wildâtype TRKAâGFP (Fig. <xref rid="humu23123-fig-0002" ref-type="fig">2</xref>D).</p>
        <p>Although many of the mutations altered the glycosylation status of TRKAâGFP and its localization, they did not completely block trafficking of the receptors to the plasma membrane. Therefore, we next questioned whether the mutants could activate various downstream signaling pathways.</p>
      </sec>
      <sec id="humu23123-sec-0170">
        <title>Autophosphorylation of TRKAâGFP Mutant Proteins</title>
        <p>We next looked at the effects of the mutations on autophosphorylation of TRKAâGFP. HeLa cells were transfected with wildâtype and mutant constructs. The basal level of autophosphorylation of wildâtype TRKAâGFP increased 2.5âfold after NGF stimulation (Fig. <xref rid="humu23123-fig-0003" ref-type="fig">3</xref>A). There was a threefold reduction in basal levels of autophosphorylation in four of the mutants, namely p.G522E, p.L657P, p.I699T, and p.R771C (<sup>***</sup>
<italic>P</italic>Â &lt;Â 0.001) and there was no induction of NGFâstimulated TRKAâGFP autophosphorylation (<sup>***</sup>
<italic>P</italic>Â &lt;Â 0.001; Fig. <xref rid="humu23123-fig-0003" ref-type="fig">3</xref>A). There were no observable differences in the basal levels of autophosphorylation, nor induction of autophosphorylation after NGF stimulation in p.G517E and p.C752S. In p.C763S, there was a threefold reduction in basal levels of autophosphorylation and NGF stimulated autophosphorylation (<sup>**</sup>
<italic>P</italic>Â &lt;Â 0.01).</p>
        <fig fig-type="Figure" xml:lang="en" id="humu23123-fig-0003" orientation="portrait" position="float">
          <label>Figure 3</label>
          <caption>
            <p>Relative Y680/681 and Y496 phosphorylation of mutant TRKA. <bold>A</bold>: Basal level of wildâtype and mutant TRKAâGFP autophosphorylation in transfected untreated HeLa cells. Response to wildâtype and mutant TRKAâGFP protein to 15Â min stimulation with 100Â ng/ml NGF. <bold>B</bold>: Basal level of Y496 phosphorylation in wildâtype and mutant TRKA proteins in untreated cells and after NGF stimulation. The bar graphs in A and B represents the mean values of <italic>n</italic>Â =Â 3 and error bars represents standard error of the mean. Statistical differences between induced phosphorylation of wildâtype and mutant TRKA are indicated as <sup>**</sup>
<italic>P</italic>Â &lt;Â 0.01 or <sup>***</sup>
<italic>P</italic>Â &lt;Â 0.001 (oneâway ANOVA, followed by Student's <italic>t</italic>âtest using a Bonferroni adjusted <italic>P</italic> value). WT, wildâtype; EV, empty vector.</p>
          </caption>
          <graphic id="nlm-graphic-7" xlink:href="HUMU-38-55-g003"/>
        </fig>
      </sec>
      <sec id="humu23123-sec-0180">
        <title>Y496 Phosphorylation of Mutant TRKAâGFP Proteins</title>
        <p>We then looked at the effect of the mutations on Y496 phosphorylation which is important for the recruitment of Shc and downstream signaling through PI3K and the Ras/MAPK pathway. HeLa cells were transfected with wildâtype and mutant constructs, and then NGF stimulated. The basal level of wildâtype TRKAâGFP Y496 phosphorylation increased threefold upon NGF stimulation (Fig. <xref rid="humu23123-fig-0003" ref-type="fig">3</xref>B). The four mutants, p.G522E, p.L657P, p.I699T, and p.R771C, which showed defective autophosphorylation, did not induce Y496 phosphorylation after NGF stimulation (<sup>***</sup>
<italic>P</italic>Â &lt;Â 0.001), whereas p.G517E and p.C752S did not alter basal nor NGFâstimulated Y496 phosphorylation. In p.C763S, there was a threefold reduction in basal Y496 phosphorylation and a 2.5âfold reduction in NGFâstimulated Y496 phosphorylation (<sup>**</sup>
<italic>P</italic>Â &lt;Â 0.01).</p>
      </sec>
      <sec id="humu23123-sec-0190">
        <title>Induction of PLCÎ³ Pathway</title>
        <p>As p.G517E and p.C752S did not seem to have any effect upon trafficking or autophosphorylation, as described above, we determined their ability to activate the PLCÎ³ pathway through monitoring calcium flux after NGF stimulation. We also tested the other mutants. HeLa cells were transfected and loaded with the calcium indicator dye rhodamineâ3. In wildâtype transfected cells, after NGF stimulation, there was an increase in basal fluorescence (Fig. <xref rid="humu23123-fig-0004" ref-type="fig">4</xref>A) to a maximum fluorescence of 2.5Â AU at <italic>t</italic>Â =Â 208Â sec (Supp. Fig. S5A). Furthermore, 90% of transfected cells responded to NGF (Supp. Fig. S5B). Treatment with U73122, a PLCÎ³ inhibitor, abolished induction of NGF increase of calcium (Supp. Fig. S5C).</p>
        <fig fig-type="Figure" xml:lang="en" id="humu23123-fig-0004" orientation="portrait" position="float">
          <label>Figure 4</label>
          <caption>
            <p>Effect of mutations on induction of PLCÎ³ pathway. <bold>A</bold>: HeLa cells were transfected with wildâtype and mutant TRKA constructs and loaded with rhodamineâ3 and response to NGF was monitored. Ionomycin was used as the positive control. Only cells that did not spontaneously fluoresce and had an ionomycin response were used for analysis. WT, wildâtype. <bold>B</bold>: No significant increase in calcium levels was observed after NGF stimulation in p.G517E transfected cells. <bold>C</bold>: There was an increase in fluorescence in p.C752S transfected cells which peaked at <italic>t</italic>Â =Â 208. <bold>D</bold>: NGF stimulation on cells transfected with p.C763S caused an increase in fluorescence but the maximum value was reduced.</p>
          </caption>
          <graphic id="nlm-graphic-9" xlink:href="HUMU-38-55-g004"/>
        </fig>
        <p>Fluorescence remained at basal levels in cells transfected with the mutant proteins that did not autophosphorylate or phosphorylate Y496 (Supp. Fig. S5A). NGF stimulation of p.G517E transfected cells did not induce an increase in red fluorescence (Fig. <xref rid="humu23123-fig-0004" ref-type="fig">4</xref>B), which remained at basal levels (<sup>**</sup>
<italic>P</italic>Â &lt;Â 0.01) and the percentage of cells responsive to NGF was 3% (Supp. Fig. S5B). There was no observable difference in the calcium response in p.C752S transfected cells (Fig. <xref rid="humu23123-fig-0004" ref-type="fig">4</xref>C) compared with the response observed in wildâtype TRKAâGFP proteins. In p.C763S transfected cells, basal fluorescence increased to a maximum value of 1.2Â AU (Fig. <xref rid="humu23123-fig-0004" ref-type="fig">4</xref>D; <sup>**</sup>
<italic>P</italic>Â &lt;Â 0.01) and only 50% of cells were NGF responsive.</p>
      </sec>
      <sec id="humu23123-sec-0200">
        <title>Neurite Outgrowth</title>
        <p>Activation of the different signaling pathways triggered by TRKA ultimately results in differentiation toward a neuronal phenotype [Huang and Reichardt, <xref rid="humu23123-bib-0017" ref-type="ref">2003</xref>]. Consequently, we looked at the effect of selected mutations on induction of neuronal differentiation. The neuroblastoma cell line SHâSY5Y was transfected with wildâtype TRKAâGFP, the mutants p.G517E, p.L657P, p.C752S, p.C763S and empty vector and treated with NGF over 9 days (Fig. <xref rid="humu23123-fig-0005" ref-type="fig">5</xref>A).</p>
        <fig fig-type="Figure" xml:lang="en" id="humu23123-fig-0005" orientation="portrait" position="float">
          <label>Figure 5</label>
          <caption>
            <p>Differentiation ability of selected mutants. <bold>A</bold>: Representative images of transfected SHâSY5Y cells treated with NGF for 9 days. WT, wildâtype; EV, empty vector. Green signal indicates transfected cells, blue DAPI nuclear stain. <bold>B</bold>: Quantification of percentage of neurite bearing cells. A neurite was defined as being two times the cell body length. <bold>C</bold>: Average neurite length was also quantified. For this all extensions however small were measured. The bar graphs in B and C represent the mean values of <italic>n</italic>Â =Â 3, with 60 cells in each repeat, and error bars represent standard error of the mean. Statistical differences are indicated as <sup>**</sup>
<italic>P</italic>Â &lt;Â 0.01 or <sup>***</sup>
<italic>P</italic>Â &lt;Â 0.001 (oneâway ANOVA, followed by Student's <italic>t</italic>âtest using a Bonferroni adjusted <italic>P</italic> value).</p>
          </caption>
          <graphic id="nlm-graphic-11" xlink:href="HUMU-38-55-g005"/>
        </fig>
        <p>After 9 days of NGF stimulation, 40% of cells transfected with wildâtype TRKAâGFP differentiated into a neuronal phenotype (Fig. <xref rid="humu23123-fig-0005" ref-type="fig">5</xref>B) and the average neurite length was 360Â AU (Fig. <xref rid="humu23123-fig-0005" ref-type="fig">5</xref>C). Although there was a significant reduction in the percentage of differentiated p.G517E transfected cells (<sup>***</sup>
<italic>P</italic>Â &lt;Â 0.001), the average neurite length was not significantly different. p.C752S did not affect neurite outgrowth nor neurite length. The p.C763S mutation resulted in a significant reduction in the percentage of differentiated cells to 20% (<sup>***</sup>
<italic>P</italic>Â &lt;Â 0.001) and a significant reduction of neurite length (<sup>***</sup>
<italic>P</italic>Â &lt;Â 0.001). p.L657P was included as a negative control and only 5% of transfected cells could be classified as differentiated, which resembles the percentage of spontaneous differentiated cells in the empty transfected control.</p>
      </sec>
      <sec id="humu23123-sec-0210">
        <title>Structural Modeling of TRKA Mutations</title>
        <p>We next modeled the structural consequences of the mutations on the kinase domain (Supp. Figs. S2 and S3C). We found that p.G517 and p.G522 are the first and third glycine residues within the ATP binding domain GxGxxG. Ligand binding and autophosphorylation of TRKA induce a conformational change that shifts TRKA into an open conformation and allows binding of ATP which increases the kinase activity [Jullien <italic>etÂ al</italic>. <xref rid="humu23123-bib-0019" ref-type="ref">2002</xref>]. p.L657 is structurally within the active site of TRKA, where it is likely to have a stabilization role. p.I699 is within the activation loop, which is essential for autophosphorylation and hence may have a role in enabling autophosphorylation to occur. p.C752, p.C763, and p.R771 are all within the catalytic domain of TRKA and hence are likely to affect activity of TRKA.</p>
      </sec>
    </sec>
    <sec id="humu23123-sec-0220">
      <title>Discussion</title>
      <p>In this study, we report seven novel missense mutations found in patients with a HSAN IV phenotype. We have undertaken a comprehensive assessment of the effects of each of these mutations on TRKA function, using a greater range of methods than has been previously reported [Greco <italic>etÂ al</italic>. <xref rid="humu23123-bib-0014" ref-type="ref">1999</xref>; Greco <italic>etÂ al</italic>. <xref rid="humu23123-bib-0015" ref-type="ref">2000</xref>; Mardy <italic>etÂ al</italic>. <xref rid="humu23123-bib-0024" ref-type="ref">2001</xref>; Miranda <italic>etÂ al</italic>. <xref rid="humu23123-bib-0027" ref-type="ref">2002</xref>]: glycosylation and membrane expression, autophosphorylation, Y496 phosphorylation, PLCÎ³ activation and effects on neurite outgrowth (summarized in Table <xref rid="humu23123-tbl-0001" ref-type="table-wrap">1</xref>).</p>
      <p>Glycosylation of TRKA is essential for its function and thus we assayed this for each of our mutations. p.G517E showed a similar glycosylation pattern to wildâtype TRKAâGFP. We observed no changes in subcellular localization for this mutant protein as full glycosylation is required for trafficking to the plasma membrane [Watson <italic>etÂ al</italic>. <xref rid="humu23123-bib-0036" ref-type="ref">1999</xref>]. p.G517E did not affect autophosphorylation and as a result downstream phosphorylation of Y496 was found to be unaffected. However, the p.G517E mutation completely abolished PLCÎ³ signaling and we found that the mutation was less efficient at promoting differentiation and neurite outgrowth. p.G517E is the first glycine in the ATP binding domain GxGxxG. Hence it is surprising that Y496 phosphorylation is observed and PLCÎ³ signaling is abolished. The attenuation of PLCÎ³ signaling may be due a conformational change within the kinase domain that alters PLCÎ³ signaling. This is the first mutation identified within the kinase domain that does not alter kinase activity of TRKA. It is also the first mutation identified to date that only affects one signaling pathway and yet is sufficient to restrict differentiation and thus must be the pathogenic mechanism behind HSAN IV. The result highlights the fact that when assessing the pathogenicity of TRKA patient mutations, it is not sufficient to just look at autophosphorylation or Y496 phosphorylation as has been done previously [Greco <italic>et al</italic>. <xref rid="humu23123-bib-0014" ref-type="ref">1999</xref>; Greco <italic>etÂ al</italic>. <xref rid="humu23123-bib-0015" ref-type="ref">2000</xref>; Mardy <italic>etÂ al</italic>. <xref rid="humu23123-bib-0024" ref-type="ref">2001</xref>; Miranda <italic>etÂ al</italic>. <xref rid="humu23123-bib-0027" ref-type="ref">2002</xref>]. Clinically the patient with p,G517E mutation had typical HSAN IV phenotype and was indistinguishable from our other cases.</p>
      <p>p.G522E mutation also showed a similar glycosylation pattern to wildâtype TRKA and hence no differences in membrane expression were observed. There was no induction of TRKA autophosphorylation after NGF stimulation. As a consequence of a lack of TRKA activation, downstream signaling through Y496 and PLCÎ³ were abolished. As this mutant protein retains membrane localization, it is likely that the primary pathogenic mechanism is absent intrinsic kinase activity. The effect of this mutation is unexpected because p.G522E resides within the ATP binding domain and autophosphorylation is not dependent on ATP binding. Hence it appears that G522 may function directly in kinase activity and changes to the structure of the kinase domain leads to no kinase function. This is confirmed by studies on a different mutation at this site, p.G522R (termed p.G516R in the article) where the mutation also rendered the protein kinaseâdead [Mardy <italic>etÂ al</italic>. <xref rid="humu23123-bib-0024" ref-type="ref">2001</xref>].</p>
      <p>p.L657P, p.I699T, and p.R771C all exhibited similar results in the assays performed. We found a decrease of fully glycosylated TRKAâGFP in these mutant proteins and the partially glycosylated 140Â kDa product was favored. We hypothesized this effect may be explained by mutationâinduced conformational changes that alter the accessibility of enzymes to the glycosylation sites. An alternative explanation could be that these mutations cause aberrant folding of the TRKA kinase domain, that may be detected by cellular proofing systems and start degrading these mutants even before they become fully glycosylated. Furthermore, these mutations had more TRKAâGFP protein in the cytoplasm than at the plasma membrane, confirming previous results that trafficking to the plasma membrane is related to glycosylation status. However, as there was some TRKAâGFP at the membrane for each of these mutations, we next sought to investigate downstream signaling pathways. In all cases, TRKAâGFP autophosphorylation was abolished. Neurite outgrowth in p.L657P (as a representative) was also abolished. As the four kinaseâdead mutants retained some membrane localization, it is likely that the primary pathogenic mechanism is absent intrinsic kinase activity. Structural modeling showed that p.G522E, p.L657P, p.I699T, and p.R771C were located in important parts of the kinase domain: the ATP binding domain, active site, activation loop, and the catalytic domain, respectively. It is likely that the mutations introduce a change to the 3D structure of the kinase domain which would lead to a lack of kinase activity. As such, it is unsurprising that autophosphorylation is affected and our results confirm that these residues have an essential role in autophosphorylation. These results are similar to those published previously where most the missense mutations were found to produce kinaseâdead mutants [Greco <italic>etÂ al</italic>. <xref rid="humu23123-bib-0014" ref-type="ref">1999</xref>; Greco <italic>etÂ al</italic>. <xref rid="humu23123-bib-0015" ref-type="ref">2000</xref>; Mardy <italic>etÂ al</italic>. <xref rid="humu23123-bib-0024" ref-type="ref">2001</xref>; Miranda <italic>etÂ al</italic>. <xref rid="humu23123-bib-0027" ref-type="ref">2002</xref>].</p>
      <p>C752S did not affect glycosylation and hence did not affect trafficking to the membrane. In addition, autophosphorylation, Y496 phosphorylation and PLCÎ³ activation were unaffected. Furthermore, neurite outgrowth data indicated that the mutation did not affect differentiation. p.C752S is within the catalytic domain but we could find no evidence of disrupted function. This heterozygous mutation was found in trans with the heterozygous kinaseâdead p.G522E mutation and no other <italic>NTRK1</italic> change was detected despite complete Sanger sequencing. Furthermore, the nucleotide change was not predicted to change or create a splice site. Thus, it appears that even though this mutation affects an evolutionary conserved residue, it is not pathogenic and in fact could be a rare but harmless polymorphism. In this family, we have failed to discover the other pathogenic mutation in <italic>NTRK1</italic>. The C752S result highlights the weakness of in silico predictions of pathogenicity and indicates functional work is necessary to call for pathogenic mutations.</p>
      <p>p.C763S is within the catalytic domain and only partially reduced both autophosphorylation and consequently Y496 phosphorylation. Nonetheless this is sufficient to cause disease. This suggests that there is an essential level of activation of TRKA required before nociceptor differentiation can take place. As we found this patient to be phenotypically indistinguishable from our other HSAN IV cases, it must be concluded that the mutations renders the TRKA signal insufficient to trigger differentiation. This is the first reported case where a reduction in TRKA signaling, but not abolition, leads to a HSAN IV phenotype.</p>
      <p>In conclusion, we report seven novel <italic>NTRK1</italic> mutations in individuals with a diagnosis of HSAN IV, and have found evidence to support pathogenicity in six. Our results highlight the fact that when assessing the pathogenicity of TRKA mutations (for example p.G517E), it is not sufficient to only assess autophosphorylation or Y496 phosphorylation, as has been done previously [Greco <italic>etÂ al</italic>. <xref rid="humu23123-bib-0014" ref-type="ref">1999</xref>; Greco <italic>etÂ al</italic>. <xref rid="humu23123-bib-0015" ref-type="ref">2000</xref>; Mardy <italic>etÂ al</italic>. <xref rid="humu23123-bib-0024" ref-type="ref">2001</xref>; Miranda <italic>etÂ al</italic>. <xref rid="humu23123-bib-0027" ref-type="ref">2002</xref>]. Similarly complete evolutionary conservation is also not an absolute predictor of pathogenicity, as we found no evidence that p.C752S was pathogenic, confirming the need for caution when interpreting the pathogenicity of unknown variants [Waxman <italic>etÂ al</italic>. <xref rid="humu23123-bib-0037" ref-type="ref">2014</xref>]. Our data highlights the complexity of TRKA function and suggests that perturbation of any part of the downstream signaling may lead to a loss of nociceptor development.</p>
    </sec>
    <sec id="humu23123-sec-0240">
      <p>
<italic>Disclosure statement</italic>: The authors declare no conflict of interest.</p>
    </sec>
    <sec sec-type="supplementary-material">
      <title>Supporting information</title>
      <supplementary-material content-type="local-data">
        <p>Disclaimer: Supplementary materials have been peerâreviewed but not copyedited.</p>
      </supplementary-material>
      <supplementary-material content-type="local-data">
        <caption>
          <p>Supp. Fig. S1: Activity of GFPâtagged and untagged wildâtype TRKA</p>
          <p>Supp. Fig. S2: TrkA structure and position of mutated residues</p>
          <p>Supp. Fig. S3: Alignment and conservation of mutated residues</p>
          <p>Supp. Fig. S4: Colocalization of TRKA with Na+/K+ ATPase</p>
          <p>Supp. Fig. S5: Activation of the PLCÎ³ pathway by TRKA mutants</p>
          <p>Supp. Table S1: Summary of functional characterization of previously identified TRKA mutations</p>
        </caption>
        <media xlink:href="HUMU-38-55-s001.pdf">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <ack id="humu23123-sec-0230">
      <title>Acknowledgments</title>
      <p>We thank the families and their physicians for their help. Ethics approval was obtained from the Cambridge East Research Ethics Committee and patients consented for DNA testing and are anonymous in the article.</p>
    </ack>
    <ref-list id="humu23123-bibl-0001">
      <title>References</title>
      <ref id="humu23123-bib-0001">
        <mixed-citation publication-type="journal" id="humu23123-cit-0001">
<string-name>
<surname>Amano</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Akiyama</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ikeda</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Morisaki</surname>
<given-names>I</given-names>
</string-name>. <year>1998</year>
<article-title>Oral manifestations of hereditary sensory and autonomic neuropathy type IV. Congenital insensitivity to pain with anhidrosis</article-title>. <source>Oral Surg Oral Med Oral Pathol Oral Radiol Endod</source>
<volume>86</volume>:<fpage>425</fpage>â<lpage>431</lpage>.<pub-id pub-id-type="pmid">9798226</pub-id></mixed-citation>
      </ref>
      <ref id="humu23123-bib-0002">
        <mixed-citation publication-type="journal" id="humu23123-cit-0002">
<string-name>
<surname>Artim</surname>
<given-names>SC</given-names>
</string-name>, <string-name>
<surname>Mendrola</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Lemmon</surname>
<given-names>MA</given-names>
</string-name>. <year>2012</year>
<article-title>Assessing the range of kinase autoinhibition mechanisms in the insulin receptor family</article-title>. <source>Biochem J</source>
<volume>448</volume>:<fpage>213</fpage>â<lpage>220</lpage>.<pub-id pub-id-type="pmid">22992069</pub-id></mixed-citation>
      </ref>
      <ref id="humu23123-bib-0003">
        <mixed-citation publication-type="journal" id="humu23123-cit-0003">
<string-name>
<surname>Axelrod</surname>
<given-names>FB</given-names>
</string-name>. <year>2002</year>
<article-title>Hereditary sensory and autonomic neuropathies. Familial dysautonomia and other HSANs</article-title>. <source>Clin Auton Res</source>
<volume>12</volume>(<issue>Suppl 1</issue>):<fpage>12</fpage>â<lpage>14</lpage>.</mixed-citation>
      </ref>
      <ref id="humu23123-bib-0004">
        <mixed-citation publication-type="journal" id="humu23123-cit-0004">
<string-name>
<surname>Adzhubei</surname>
<given-names>IA</given-names>
</string-name>, <string-name>
<surname>Schmidt</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Peshkin</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Ramensky</surname>
<given-names>VE</given-names>
</string-name>, <string-name>
<surname>Gerasimova</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Bork</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Kondrashov</surname>
<given-names>AS</given-names>
</string-name>, <string-name>
<surname>Sunyaev</surname>
<given-names>SR</given-names>
</string-name>. <year>2010</year>
<article-title>A method and server for predicting damaging missense mutations</article-title>. <source>Nat Methods</source>
<volume>7</volume>:<fpage>248</fpage>â<lpage>249</lpage>.<pub-id pub-id-type="pmid">20354512</pub-id></mixed-citation>
      </ref>
      <ref id="humu23123-bib-0005">
        <mixed-citation publication-type="journal" id="humu23123-cit-0005">
<string-name>
<surname>Bannwarth</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Kostine</surname>
<given-names>M</given-names>
</string-name>. <year>2014</year>
<article-title>Targeting nerve growth factor (NGF) for pain management: what does the future hold for NGF antagonists?</article-title>
<source>Drugs</source>
<volume>74</volume>:<fpage>619</fpage>â<lpage>626</lpage>.<pub-id pub-id-type="pmid">24691709</pub-id></mixed-citation>
      </ref>
      <ref id="humu23123-bib-0006">
        <mixed-citation publication-type="journal" id="humu23123-cit-0006">
<string-name>
<surname>Barker</surname>
<given-names>PA</given-names>
</string-name>, <string-name>
<surname>LomenâHoerth</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Gensch</surname>
<given-names>EM</given-names>
</string-name>, <string-name>
<surname>Meakin</surname>
<given-names>SO</given-names>
</string-name>, <string-name>
<surname>Glass</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Shooter</surname>
<given-names>EM</given-names>
</string-name>. <year>1993</year>
<article-title>Tissueâspecific alternative splicing generates two isoforms of the trkA receptor</article-title>. <source>J Biol Chem</source>
<volume>268</volume>:<fpage>15150</fpage>â<lpage>15157</lpage>.<pub-id pub-id-type="pmid">8325889</pub-id></mixed-citation>
      </ref>
      <ref id="humu23123-bib-0007">
        <mixed-citation publication-type="journal" id="humu23123-cit-0007">
<string-name>
<surname>BarâOn</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Weigl</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Parvari</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Katz</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Weitz</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Steinberg</surname>
<given-names>T</given-names>
</string-name>. <year>2002</year>
<article-title>Congenital insensitivity to pain. Orthopedic manifestations</article-title>. <source>J Bone Joint Surg Br</source>
<volume>84</volume>:<fpage>252</fpage>â<lpage>257</lpage>.<pub-id pub-id-type="pmid">11922368</pub-id></mixed-citation>
      </ref>
      <ref id="humu23123-bib-0008">
        <mixed-citation publication-type="journal" id="humu23123-cit-0008">
<string-name>
<surname>Beiglman</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Levy</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Hadad</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Pinsk</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Haim</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Fruchtman</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Levy</surname>
<given-names>R</given-names>
</string-name>. <year>2009</year>
<article-title>Abnormal neutrophil chemotactic activity in children with congenital insensitivity to pain with anhidrosis (CIPA): the role of nerve growth factors</article-title>. <source>Clin Immunol</source>
<volume>130</volume>:<fpage>365</fpage>â<lpage>372</lpage>.<pub-id pub-id-type="pmid">18955016</pub-id></mixed-citation>
      </ref>
      <ref id="humu23123-bib-0009">
        <mixed-citation publication-type="journal" id="humu23123-cit-0009">
<string-name>
<surname>Cunningham</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Stephens</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Kaplan</surname>
<given-names>DR</given-names>
</string-name>, <string-name>
<surname>Greene</surname>
<given-names>LA</given-names>
</string-name>. <year>1997</year>
<article-title>Autophosphorylation of activation loop tyrosine regulates signaling by the TRK nerve growth factor receptor</article-title>. <source>J Biol Chem</source>
<volume>272</volume>:<fpage>10957</fpage>â<lpage>10967</lpage>.<pub-id pub-id-type="pmid">9099755</pub-id></mixed-citation>
      </ref>
      <ref id="humu23123-bib-0010">
        <mixed-citation publication-type="journal" id="humu23123-cit-0010">
<string-name>
<surname>Cunningham</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Greene</surname>
<given-names>LA</given-names>
</string-name>. <year>1998</year>
<article-title>A functionâstructure model for NGFâactivated Trk</article-title>. <source>EMBO J</source>
<volume>17</volume>:<fpage>7282</fpage>â<lpage>7293</lpage>.<pub-id pub-id-type="pmid">9857185</pub-id></mixed-citation>
      </ref>
      <ref id="humu23123-bib-0011">
        <mixed-citation publication-type="journal" id="humu23123-cit-0011">
<string-name>
<surname>Datta</surname>
<given-names>SR</given-names>
</string-name>, <string-name>
<surname>Brunet</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Greenberg</surname>
<given-names>ME</given-names>
</string-name>. <year>1999</year>
<article-title>Cellular survival: a play in three Akts</article-title>. <source>Genes Dev</source>
<volume>13</volume>:<fpage>2905</fpage>â<lpage>2927</lpage>.<pub-id pub-id-type="pmid">10579998</pub-id></mixed-citation>
      </ref>
      <ref id="humu23123-bib-0012">
        <mixed-citation publication-type="journal" id="humu23123-cit-0012">
<string-name>
<surname>Dikic</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Batzer</surname>
<given-names>AG</given-names>
</string-name>, <string-name>
<surname>Blaikie</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Obermeier</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Ullrich</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Schlessinger</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Margolis</surname>
<given-names>M</given-names>
</string-name>. <year>1995</year>
<article-title>Shc binding to nerve growth factor receptor is mediated by the phosphotyrosine interaction domain</article-title>. <source>J Biol Chem</source>
<volume>270</volume>:<fpage>15125</fpage>â<lpage>15129</lpage>.<pub-id pub-id-type="pmid">7541035</pub-id></mixed-citation>
      </ref>
      <ref id="humu23123-bib-0013">
        <mixed-citation publication-type="journal" id="humu23123-cit-0013">
<string-name>
<surname>Dubin</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Patapoutian</surname>
<given-names>A</given-names>
</string-name>. <year>2010</year>
<article-title>Nociceptors: the sensors of the pain pathway</article-title>. <source>J Clin Invest</source>
<volume>120</volume>:<fpage>3760</fpage>â<lpage>3772</lpage>.<pub-id pub-id-type="pmid">21041958</pub-id></mixed-citation>
      </ref>
      <ref id="humu23123-bib-0014">
        <mixed-citation publication-type="journal" id="humu23123-cit-0014">
<string-name>
<surname>Greco</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Villa</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Tubino</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Romano</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Penso</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Pierotti</surname>
<given-names>MA</given-names>
</string-name>. <year>1999</year>
<article-title>A novel NTRK1 mutation associated with congenital insensitivity to pain with anhidrosis</article-title>. <source>Am J Hum Genet</source>
<volume>64</volume>:<fpage>1207</fpage>â<lpage>1210</lpage>.<pub-id pub-id-type="pmid">10090906</pub-id></mixed-citation>
      </ref>
      <ref id="humu23123-bib-0015">
        <mixed-citation publication-type="journal" id="humu23123-cit-0015">
<string-name>
<surname>Greco</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Villa</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Fusetti</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Orlandi</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Pierotti</surname>
<given-names>MA</given-names>
</string-name>. <year>2000</year>
<article-title>The Gly571Arg mutation, associated with the autonomic and sensory disorder congenital insensitivity to pain with anhidrosis, causes the inactivation of the Ntrk1/ nerve growth factor receptor</article-title>. <source>J Cell Physiol</source>
<volume>182</volume>:<fpage>127</fpage>â<lpage>133</lpage>.<pub-id pub-id-type="pmid">10567924</pub-id></mixed-citation>
      </ref>
      <ref id="humu23123-bib-0016">
        <mixed-citation publication-type="journal" id="humu23123-cit-0016">
<string-name>
<surname>Hepburn</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Prajsnar</surname>
<given-names>TK</given-names>
</string-name>, <string-name>
<surname>Klapholz</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Moreno</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Loynes</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Ogryzko</surname>
<given-names>NV</given-names>
</string-name>, <string-name>
<surname>Brown</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Shiebler</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Hegyi</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Antrobus</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Hammond</surname>
<given-names>KL</given-names>
</string-name>, <string-name>
<surname>Connolly</surname>
<given-names>J</given-names>
</string-name> etÂ al. <year>2014</year>
<article-title>Innate immunity. A Spaetzleâlike role for nerve growth factor Î² in vertebrate immunity to Staphylococcus aureus</article-title>. <source>Science</source>
<volume>346</volume>:<fpage>641</fpage>â<lpage>646</lpage>.<pub-id pub-id-type="pmid">25359976</pub-id></mixed-citation>
      </ref>
      <ref id="humu23123-bib-0017">
        <mixed-citation publication-type="journal" id="humu23123-cit-0017">
<string-name>
<surname>Huang</surname>
<given-names>EJ</given-names>
</string-name>, <string-name>
<surname>Reichardt</surname>
<given-names>LF</given-names>
</string-name>. <year>2003</year>
<article-title>Trk receptors: roles in signal transduction</article-title>. <source>Annu Rev Biochem</source>
<volume>72</volume>:<fpage>609</fpage>â<lpage>642</lpage>.<pub-id pub-id-type="pmid">12676795</pub-id></mixed-citation>
      </ref>
      <ref id="humu23123-bib-0018">
        <mixed-citation publication-type="journal" id="humu23123-cit-0018">
<string-name>
<surname>Ismail</surname>
<given-names>EA</given-names>
</string-name>, <string-name>
<surname>AlâShammari</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Anim</surname>
<given-names>JT</given-names>
</string-name>, <string-name>
<surname>Moosa</surname>
<given-names>A</given-names>
</string-name>. <year>1998</year>
<article-title>Congenital insensitivity to pain with anhidrosis: lack of eccrine sweat gland innervation confirmed</article-title>. <source>J Child Neurol</source>
<volume>13</volume>:<fpage>243</fpage>â<lpage>246</lpage>.<pub-id pub-id-type="pmid">9620018</pub-id></mixed-citation>
      </ref>
      <ref id="humu23123-bib-0019">
        <mixed-citation publication-type="journal" id="humu23123-cit-0019">
<string-name>
<surname>Jullien</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Guili</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Reichardt</surname>
<given-names>LF</given-names>
</string-name>, <string-name>
<surname>Rudkin</surname>
<given-names>BB</given-names>
</string-name>. <year>2002</year>
<article-title>Molecular kinetics of nerve growth factor receptor trafficking and activation</article-title>. <source>J Biol Chem</source>
<volume>277</volume>:<fpage>38700</fpage>â<lpage>38708</lpage>.<pub-id pub-id-type="pmid">12055187</pub-id></mixed-citation>
      </ref>
      <ref id="humu23123-bib-0020">
        <mixed-citation publication-type="journal" id="humu23123-cit-0020">
<string-name>
<surname>Kumar</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Henikoff</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ng</surname>
<given-names>PC</given-names>
</string-name>. <year>2009</year>
<article-title>Predicting the effects of coding nonâsynonymous variants on protein function using the SIFT algorithm</article-title>. <source>Nat Protoc</source>
<volume>4</volume>:<fpage>1073</fpage>â<lpage>81</lpage>.<pub-id pub-id-type="pmid">19561590</pub-id></mixed-citation>
      </ref>
      <ref id="humu23123-bib-0021">
        <mixed-citation publication-type="journal" id="humu23123-cit-0021">
<string-name>
<surname>Lonze</surname>
<given-names>BE</given-names>
</string-name>, <string-name>
<surname>Riccio</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Cohen</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ginty</surname>
<given-names>DD</given-names>
</string-name>. <year>2002</year>
<article-title>Apoptosis, axonal growth defects, and degeneration of peripheral neurons in mice lacking CREB</article-title>. <source>Neuron</source>
<volume>34</volume>:<fpage>371</fpage>â<lpage>385</lpage>.<pub-id pub-id-type="pmid">11988169</pub-id></mixed-citation>
      </ref>
      <ref id="humu23123-bib-0022">
        <mixed-citation publication-type="journal" id="humu23123-cit-0022">
<string-name>
<surname>McWilliam</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Uludag</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Squizzato</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Park</surname>
<given-names>YM</given-names>
</string-name>, <string-name>
<surname>Buso</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Cowley</surname>
<given-names>AP</given-names>
</string-name>, <string-name>
<surname>Lopez</surname>
<given-names>R</given-names>
</string-name>. <year>2013</year>
<article-title>Analysis tool web services from the EMBLâEBI</article-title>. <source>Nucleic Acids Res</source>
<volume>41</volume>:<fpage>597</fpage>â<lpage>600</lpage>.</mixed-citation>
      </ref>
      <ref id="humu23123-bib-0023">
        <mixed-citation publication-type="journal" id="humu23123-cit-0023">
<string-name>
<surname>MacDonald</surname>
<given-names>JIS</given-names>
</string-name>, <string-name>
<surname>Gryz</surname>
<given-names>EA</given-names>
</string-name>, <string-name>
<surname>Kubi</surname>
<given-names>CJ</given-names>
</string-name>, <string-name>
<surname>Verdi</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Meakin</surname>
<given-names>SO</given-names>
</string-name>. <year>2000</year>
<article-title>Direct binding of the signaling adapter protein Grb2 to the activation loop tyrosines on the nerve growth factor receptor tyrosine kinase, TRKA</article-title>. <source>J Biol Chem</source>
<volume>275</volume>:<fpage>18225</fpage>â<lpage>18223</lpage>.<pub-id pub-id-type="pmid">10748052</pub-id></mixed-citation>
      </ref>
      <ref id="humu23123-bib-0024">
        <mixed-citation publication-type="journal" id="humu23123-cit-0024">
<string-name>
<surname>Mardy</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Miura</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Endo</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Matsuda</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Indo</surname>
<given-names>Y</given-names>
</string-name>. <year>2001</year>
<article-title>Congenital insensitivity to pain with anhidrosis (CIPA): effect of TRKA (NTRK1) missense mutations on autophosphorylation of the receptor tyrosine kinase for nerve growth factor</article-title>. <source>Hum Mol Genet</source>
<volume>10</volume>:<fpage>179</fpage>â<lpage>188</lpage> .<pub-id pub-id-type="pmid">11159935</pub-id></mixed-citation>
      </ref>
      <ref id="humu23123-bib-0025">
        <mixed-citation publication-type="journal" id="humu23123-cit-0025">
<string-name>
<surname>Marmigere</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Ernfors</surname>
<given-names>P</given-names>
</string-name>. <year>2007</year>
<article-title>Specification and connectivity of neuronal subtypes in the sensory lineage</article-title>. <source>Nat Rev Neurosci</source>
<volume>8</volume>:<fpage>14</fpage>â<lpage>127</lpage>.</mixed-citation>
      </ref>
      <ref id="humu23123-bib-0026">
        <mixed-citation publication-type="journal" id="humu23123-cit-0026">
<string-name>
<surname>MartinâZanca</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Oskam</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Mitra</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Copeland</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Barbacid</surname>
<given-names>M</given-names>
</string-name>. <year>1989</year>
<article-title>Molecular and biochemical characterization of the human trk protoâoncogene</article-title>. <source>Mol Cell Biol</source>
<volume>9</volume>:<fpage>24</fpage>â<lpage>33</lpage>.<pub-id pub-id-type="pmid">2927393</pub-id></mixed-citation>
      </ref>
      <ref id="humu23123-bib-0027">
        <mixed-citation publication-type="journal" id="humu23123-cit-0027">
<string-name>
<surname>Miranda</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Virgilio</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>Selleri</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Zanotti</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Pagliardini</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Pierotti</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Greco</surname>
<given-names>A</given-names>
</string-name>. <year>2002</year>
<article-title>Novel pathogenic mechanisms of congenital insensitivity to pain with anhidrosis genetic disorder unveiled by functional analysis of neurotrophic tyrosine receptor kinase type 1/ nerve growth factor receptor mutations</article-title>. <source>J Biol Chem</source>
<volume>277</volume>:<fpage>6455</fpage>â<lpage>6462</lpage>.<pub-id pub-id-type="pmid">11719521</pub-id></mixed-citation>
      </ref>
      <ref id="humu23123-bib-0028">
        <mixed-citation publication-type="journal" id="humu23123-cit-0028">
<string-name>
<surname>Mitchel</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Blasier</surname>
<given-names>KR</given-names>
</string-name>, <string-name>
<surname>Jeffery</surname>
<given-names>ED</given-names>
</string-name>, <string-name>
<surname>Ross</surname>
<given-names>MW</given-names>
</string-name>, <string-name>
<surname>Pullikuth</surname>
<given-names>AK</given-names>
</string-name>, <string-name>
<surname>Suo</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Park</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Smiley</surname>
<given-names>WR</given-names>
</string-name>, <string-name>
<surname>Lo</surname>
<given-names>KW</given-names>
</string-name>, <string-name>
<surname>Shabanowitz</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Deppmann</surname>
<given-names>CD</given-names>
</string-name>, <string-name>
<surname>Trinidad</surname>
<given-names>JC</given-names>
</string-name> etÂ al. <year>2012</year>
<article-title>Trk activation of the ERK1/2 Kinase pathway stimulates intermediate chain phosphorylation and recruits cytoplasmic dynein to signaling endosomes for retrograde axonal transport</article-title>. <source>J Neurosci</source>
<volume>32</volume>:<fpage>15495</fpage>â<lpage>15510</lpage>.<pub-id pub-id-type="pmid">23115187</pub-id></mixed-citation>
      </ref>
      <ref id="humu23123-bib-0029">
        <mixed-citation publication-type="journal" id="humu23123-cit-0029">
<string-name>
<surname>Nahorski</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>AlâGazali</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Hertecant</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Owen</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Borner</surname>
<given-names>GH</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>YC</given-names>
</string-name>, <string-name>
<surname>Benn</surname>
<given-names>CL</given-names>
</string-name>, <string-name>
<surname>Carvalho</surname>
<given-names>OP</given-names>
</string-name>, <string-name>
<surname>Shaikh</surname>
<given-names>SS</given-names>
</string-name>, <string-name>
<surname>Phelan</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Robinson</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Royle</surname>
<given-names>SJ</given-names>
</string-name>, <string-name>
<surname>Woods</surname>
<given-names>CG</given-names>
</string-name>. <year>2015</year>
<article-title>A novel disorder reveals clathrin heavy chainâ22 is essential for human pain and touch development</article-title>. <source>Brain</source>
<volume>138</volume>:<fpage>2147</fpage>â<lpage>2160</lpage>.<pub-id pub-id-type="pmid">26068709</pub-id></mixed-citation>
      </ref>
      <ref id="humu23123-bib-0030">
        <mixed-citation publication-type="journal" id="humu23123-cit-0030">
<string-name>
<surname>Obermeier</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Halfter</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Wiesmuller</surname>
<given-names>KH</given-names>
</string-name>, <string-name>
<surname>Jung</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Schlessinger</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Ullrich</surname>
<given-names>A</given-names>
</string-name>. <year>1993</year>
<article-title>Tyrosine 785 is a major determinant of Trkâsubstrate interaction</article-title>. <source>EMBO J</source>
<volume>12</volume>:<fpage>933</fpage>â<lpage>941</lpage>.<pub-id pub-id-type="pmid">8384556</pub-id></mixed-citation>
      </ref>
      <ref id="humu23123-bib-0031">
        <mixed-citation publication-type="journal" id="humu23123-cit-0031">
<string-name>
<surname>Riccio</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Ahn</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Davenport</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Blendy</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Ginty</surname>
<given-names>DD</given-names>
</string-name>. <year>1999</year>
<article-title>Mediation by a CREB family transcription factor of NGFâdependent survival of sympathetic neurons</article-title>. <source>Science</source>
<volume>286</volume>:<fpage>2358</fpage>â<lpage>2361</lpage>.<pub-id pub-id-type="pmid">10600750</pub-id></mixed-citation>
      </ref>
      <ref id="humu23123-bib-0032">
        <mixed-citation publication-type="journal" id="humu23123-cit-0032">
<string-name>
<surname>Rosemberg</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Marie</surname>
<given-names>SK</given-names>
</string-name>, <string-name>
<surname>Kliemann</surname>
<given-names>S</given-names>
</string-name>. <year>1994</year>
<article-title>Congenital insensitivity to pain with anhidrosis (hereditary sensory and autonomic neuropathy type IV)</article-title>. <source>Pediat Neurol</source>
<volume>11</volume>:<fpage>50</fpage>â<lpage>56</lpage>.<pub-id pub-id-type="pmid">7527213</pub-id></mixed-citation>
      </ref>
      <ref id="humu23123-bib-0033">
        <mixed-citation publication-type="journal" id="humu23123-cit-0033">
<string-name>
<surname>Sali</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Blundell</surname>
<given-names>TL</given-names>
</string-name>. <year>1993</year>
<article-title>Comparative protein modelling by satisfaction of spatial restraints</article-title>. <source>J Mol Biol</source>
<volume>234</volume>:<fpage>779</fpage>â<lpage>815</lpage>.<pub-id pub-id-type="pmid">8254673</pub-id></mixed-citation>
      </ref>
      <ref id="humu23123-bib-0034">
        <mixed-citation publication-type="journal" id="humu23123-cit-0034">
<string-name>
<surname>Spierings</surname>
<given-names>EL</given-names>
</string-name>, <string-name>
<surname>Fidelholtz</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Wolfram</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Smith</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>Brown</surname>
<given-names>MT</given-names>
</string-name>, <string-name>
<surname>West</surname>
<given-names>CR</given-names>
</string-name>. <year>2014</year>
<article-title>A phase III placeboâ and oxycodoneâcontrolled study of tanezumanb in adults with osteoarthritis pain of the hip or knee: response</article-title>. <source>Pain</source>
<volume>155</volume>:<fpage>2432</fpage>â<lpage>2333</lpage>.</mixed-citation>
      </ref>
      <ref id="humu23123-bib-0035">
        <mixed-citation publication-type="journal" id="humu23123-cit-0035">
<string-name>
<surname>Veale</surname>
<given-names>EL</given-names>
</string-name>, <string-name>
<surname>AlâMoubarak</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Bajaria</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Omoto</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Cao</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Tucker</surname>
<given-names>SJ</given-names>
</string-name>, <string-name>
<surname>Stevens</surname>
<given-names>EB</given-names>
</string-name>, <string-name>
<surname>Mathie</surname>
<given-names>A</given-names>
</string-name>. <year>2014</year>
<article-title>Influence of the N terminus on the biophysical properties and pharmacology of TREK1 potassium channels</article-title>. <source>Mol Pharmacol</source>
<volume>85</volume>:<fpage>671</fpage>â<lpage>81</lpage>.<pub-id pub-id-type="pmid">24509840</pub-id></mixed-citation>
      </ref>
      <ref id="humu23123-bib-0036">
        <mixed-citation publication-type="journal" id="humu23123-cit-0036">
<string-name>
<surname>Watson</surname>
<given-names>FL</given-names>
</string-name>, <string-name>
<surname>Porcionatto</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Bhattacharyya</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Stiles</surname>
<given-names>CD</given-names>
</string-name>, <string-name>
<surname>Segal</surname>
<given-names>RA</given-names>
</string-name>. <year>1999</year>
<article-title>TRKA glycosylation regulates receptor localization and activity</article-title>. <source>J Neurobiol</source>
<volume>39</volume>:<fpage>323</fpage>â<lpage>36</lpage>.<pub-id pub-id-type="pmid">10235685</pub-id></mixed-citation>
      </ref>
      <ref id="humu23123-bib-0037">
        <mixed-citation publication-type="journal" id="humu23123-cit-0037">
<string-name>
<surname>Waxman</surname>
<given-names>SG</given-names>
</string-name>, <string-name>
<surname>Merkies</surname>
<given-names>IS</given-names>
</string-name>, <string-name>
<surname>Gerrits</surname>
<given-names>MM</given-names>
</string-name>, <string-name>
<surname>DibâHajj</surname>
<given-names>SD</given-names>
</string-name>, <string-name>
<surname>Lauria</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Cox</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Wood</surname>
<given-names>JN</given-names>
</string-name>, <string-name>
<surname>Woods</surname>
<given-names>CG</given-names>
</string-name>, <string-name>
<surname>Drenth</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Faber</surname>
<given-names>CG</given-names>
</string-name>. <year>2014</year>
<article-title>Sodium channel genes in painârelated disorders: phenotypeâgenotype associations and recommendations for clinical use</article-title>. <source>Lancet Neurol</source>
<volume>13</volume>:<fpage>1152</fpage>â<lpage>1160</lpage>.<pub-id pub-id-type="pmid">25316021</pub-id></mixed-citation>
      </ref>
      <ref id="humu23123-bib-0038">
        <mixed-citation publication-type="journal" id="humu23123-cit-0038">
<string-name>
<surname>Yuang</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Yankner</surname>
<given-names>BA</given-names>
</string-name>. <year>2000</year>
<article-title>Apoptosis in the nervous system</article-title>. <source>Nature</source>
<volume>407</volume>:<fpage>802</fpage>â<lpage>809</lpage>.<pub-id pub-id-type="pmid">11048732</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record></GetRecord></OAI-PMH>